Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 0.81 |
| ▸ | CCNE2 | O96020 | 7/20 | 0.81 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.81 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.73 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.73 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.73 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.73 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.73 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.73 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.73 |
| ▸ | CDK9 | P50750 | 12/20 | 0.73 |
| ▸ | CDK7 | P50613 | 4/20 | 0.73 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.73 |
| ▸ | CCNH | P51946 | 3/20 | 0.73 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.73 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24413607 | 0.92 | CDK2 (0.79) | CDK2CCNE2CCNE1HDAC3HDAC4 | |
| SCHEMBL24758393 | 0.91 | CDK2 (0.83) | CDK2CCNE2CCNE1HDAC3HDAC4 | |
| SCHEMBL20897375 | 0.90 | CDK2 (0.76) | CDK2CCNE2CCNE1HDAC3HDAC4 | |
| SCHEMBL4929170 | 0.89 | CDK2 (1.00) | CDK2CCNE2CCNE1HDAC3HDAC4 | |
| SCHEMBL20897371 | 0.89 | HDAC3 (0.86) | CDK2CCNE2CCNE1HDAC3HDAC4 | |
| SCHEMBL20905302 | 0.89 | CDK2 (1.00) | CDK2CCNE2CCNE1HDAC3HDAC4 | |
| SCHEMBL26399636 | 0.89 | CDK2 (0.85) | CDK2CCNE2CCNE1HDAC3HDAC4 | |
| SCHEMBL24528750 | 0.88 | CDK2 (0.84) | CDK2CCNE2CCNE1HDAC3HDAC4 | |
| SCHEMBL18613589 | 0.88 | CDK2 (0.84) | CDK2CCNE2CCNE1HDAC3HDAC4 | |
| SCHEMBL26129922 | 0.88 | CDK2 (0.81) | CDK2CCNE2CCNE1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023114455-A1 | DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20220153751-A1 | BIFUNCTIONAL COMPOUNDS | BIOTHERYX, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| EP-3445760-B1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 9 (CDK9) BY CONJUGATION OF CDK9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3445760-B1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 9 (CDK9) BY CONJUGATION OF CDK9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11236103-B2 | Bifunctional compounds | BIOTHERYX, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-3830093-A1 | BIFUNCTIONAL COMPOUNDS AS CDK MODULATORS | Biotheryx, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20200048277-A1 | BIFUNCTIONAL COMPOUNDS | BIOTHERYX, INC. | 2020-02-13 | — | — | US | disclosed |
| WO-2020023782-A1 | BIFUNCTIONAL COMPOUNDS AS CDK MODULATORS | BIOTHERYX, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20190111143-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 9 (CDK9) BY CONJUGATION OF CDK9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-04-18 | — | — | US | disclosed |
| US-20190111143-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 9 (CDK9) BY CONJUGATION OF CDK9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-04-18 | — | — | US | disclosed |
| WO-2017185023-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 9 (CDK9) BY CONJUGATION OF CDK9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048277-A1 | BIFUNCTIONAL COMPOUNDS | CDK2, CDK6, CDK5 | CDK2 1/4885CCNE2 52/4885CCNE1 47/4885 |
| US-11236103-B2 | Bifunctional compounds | CDK2, CDK6, CDK5 | CDK2 1/4885CCNE2 52/4885CCNE1 47/4885 |
| US-20190111143-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 9 (CDK9) BY CONJUGATION OF CDK9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | CDK9, CDK19, CDKL1 | CDK2 9/4885CCNE2 84/4885CCNE1 52/4885 |
| US-20220153751-A1 | BIFUNCTIONAL COMPOUNDS | CDK2, CDK6, CDK5 | CDK2 1/4885CCNE2 52/4885CCNE1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.